Comparative clinical outcomes and safety of finerenone, SGLT2 inhibitors, RAS inhibitors and ARNI in heart failure with preserved or mildly reduced ejection fraction: a systematic review and network meta-analysis
Vergleichende klinische Outcomes und Sicherheit von Finerenon, SGLT2-Inhibitoren, RAS-Inhibitoren und ARNI bei Herzinsuffizienz mit erhaltener oder leicht verminderter Ejektionsfraktion: systematische Übersicht und Netzwerk-Metaanalyse
Frontiers in Pharmacology · 15.05.2026 · 17
DOI: 10.3389/fphar.2026.1813205 ↗Auf einen Blick
27 RCTs mit 65.929 Patient:innen: Finerenon war gegenüber Placebo mit weniger CV-Todesfällen und weniger Verschlechterungen der Herzinsuffizienz verbunden.
Fragestellung
Wie unterscheiden sich Wirksamkeit und Sicherheit von Finerenon, SGLT2i, RASi und ARNI bei HFpEF oder HFmrEF?
Methode
Systematische Suche in PubMed, Embase, Cochrane Library und Web of Science bis 3. Januar 2026; Netzwerk-Metaanalyse von RCTs.
Ergebnisse
27 RCTs mit 65.929 Patient:innen. Gegenüber Placebo: Finerenon senkte CV-Tod (OR 0,89; 95 %-KI 0,82–0,95) und HF-Verschlechterung (OR 0,75; 95 %-KI 0,71–0,79), erhöhte aber renale Kompositendpunkte (OR 1,42; 95 %-KI 1,10–1,84).
Einschränkungen
Die meisten Vergleiche waren indirekt.
Schlussfolgerung der Autor:innen
Im Vergleich zu Placebo war Finerenon mit geringerem Risiko für CV-Tod und HF-Verschlechterung verbunden. Für die meisten Vergleiche lagen nur indirekte Daten vor; weitere Vergleiche blieben ohne signifikante Unterschiede.
Kernaussagen
- Finerenon vs. Placebo: weniger CV-Tod und HF-Verschlechterung
- Renale Kompositendpunkte unter Finerenon häufiger
- Die meisten Behandlungsvergleiche waren indirekt
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 15.05.2026. Verfasst von Zimin Fu und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Although pharmacological therapies for heart failure have advanced, direct comparative evidence on the clinical outcomes and safety of finerenone versus other agents remains limited in HFpEF or HFmrEF.
Objective
A network meta-analysis was conducted to compare clinical outcomes and safety among finerenone, sodium–glucose cotransporter 2 inhibitors (SGLT2i), renin–angiotensin system inhibitors (RASi) and angiotensin receptor–neprilysin inhibitors (ARNI) in patients with HFpEF or HFmrEF.
Methods
A comprehensive systematic search was conducted across PubMed, Embase, the Cochrane Library, and Web of Science from database inception to 3 January 2026. Randomized controlled trials (RCTs) were included, and a network meta-analysis was performed to evaluate cardiovascular (CV) death, worsening heart failure (HF) events, composite renal outcomes, all-cause mortality, total HF hospitalizations, and adverse events.
Results
A total of 27 RCTs involving 65,929 patients were included. Compared with placebo, finerenone was associated with lower risk of CV death (OR = 0.89, 95% CI 0.82–0.95) and worsening HF events (OR = 0.75, 95% CI 0.71–0.79), but higher risk of composite renal outcomes (OR = 1.42, 95% CI 1.10–1.84). No significant differences in CV death or all-cause mortality. In indirect comparisons, finerenone was associated with lower risk of worsening HF events versus canagliflozin (OR = 2.12, 95% CI 1.13–3.98) and RASi (OR = 1.21, 95% CI 1.03–1.42). Sotagliflozin (OR = 0.61, 95% CI 0.50–0.74) and empagliflozin (OR = 0.83, 95% CI 0.69–0.99) were associated with lower risk of total HF hospitalizations. Relative to finerenone, canagliflozin (OR = 1.53, 95% CI 1.25–1.88) and RASi (OR = 1.31, 95% CI 1.10–1.57) were associated with higher risk of adverse events.
Conclusion
Compared with placebo, finerenone was associated with lower risk of CV death and worsening HF events. As most comparisons between interventions were indirect, sotagliflozin and empagliflozin were associated with lower risk of total HF hospitalizations relative to finerenone, whereas ARNI and empagliflozin were associated with lower risk of composite renal outcomes, and canagliflozin and RASi with higher risk of adverse events. No significant differences were observed between interventions for CV death or all-cause mortality.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.
- Department of Gastroenterology, First Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China.
- Department of Rehabilitation, First Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.
Zitieren
APA
Fu, Z., Chen, X., Liu, H., Yang, J., Jin, T., Liu, T., & Ta, G. (2026). Comparative clinical outcomes and safety of finerenone, SGLT2 inhibitors, RAS inhibitors and ARNI in heart failure with preserved or mildly reduced ejection fraction: a systematic review and network meta-analysis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1813205
Vancouver
Fu Z, Chen X, Liu H, Yang J, Jin T, Liu T, et al. Comparative clinical outcomes and safety of finerenone, SGLT2 inhibitors, RAS inhibitors and ARNI in heart failure with preserved or mildly reduced ejection fraction: a systematic review and network meta-analysis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1813205
BibTeX
@article{Fu2026,
author = {Fu, Zimin and Chen, Xin and Liu, Haifeng and Yang, Jia and Jin, Tonghui and Liu, Tiejun and Ta, Guang},
title = {Comparative clinical outcomes and safety of finerenone, SGLT2 inhibitors, RAS inhibitors and ARNI in heart failure with preserved or mildly reduced ejection fraction: a systematic review and network meta-analysis},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1813205}
}
EUVIMED